Skip to main content
BHI in the News

Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners – BHI’s EIR Ram Aiyar Joins the Team

By February 19, 2016No Comments

NewImage

Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.

Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001).  Funds from the Series A financing will be used to progress COR-001 into Phase I/II clinical trials during 2016, as well as to advance the company’s preclinical pipeline.

{iframe}http://corvidiatx.com/Corvidia%20Press%20Release%202016-02-16.pdf{/iframe}

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.